22 May 2013
Keywords: pharmamar, yondelis, enters, ph, ii, cog, trial
Article | 24 March 2008
Spanish pharmaceutical firm PharmaMar has initiated a Phase II multicenter study of Yondelis (trabectedin) in children with recurrent
rhabdomyosarcoma, Ewing's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 March 2008
17 March 2008
21 May 2013
© 2013 thepharmaletter.com